Viridian Therapeutics, Inc. (1S1.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:05AM CEST
| Previous close | 12.30 |
| Open | 11.70 |
| Bid | 11.70 x N/A |
| Ask | 11.90 x N/A |
| Day's range | 11.70 - 11.70 |
| 52-week range | 10.20 - 25.20 |
| Volume | |
| Avg. volume | 7 |
| Market cap | 746.723M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.13 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.20 |
Business WireViridian Therapeutics to Participate in Upcoming May Investor Conferences
WALTHAM, Mass., May 10, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May:
Simply Wall St.Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Viridian Therapeutics ( NASDAQ:VRDN ) First Quarter 2024 Results Key Financial Results Net loss: US$48.5m (loss...
- GuruFocus.com
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Discover key insights from VRDN's Q1 2024 earnings, including trial successes, financial stability, and future regulatory plans.
© 2024 Yahoo. All rights reserved.